Homology Medicines, Inc.

NasdaqGS:FIXX Stock Report

Mkt Cap: US$87.9m

Homology Medicines Past Performance

How has Homology Medicines performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


0.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FIXX is currently unprofitable.

Growing Profit Margin: FIXX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FIXX is unprofitable, but has reduced losses over the past 5 years at a rate of 0.6% per year.

Accelerating Growth: Unable to compare FIXX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FIXX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).


Return on Equity

High ROE: FIXX has a negative Return on Equity (-2.05%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies